|
|
|
|
| LEADER |
04970nam a2200589 4500 |
| 001 |
on1007290591 |
| 003 |
OCoLC |
| 005 |
20180501122038.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
171024s2017 maua ob 000 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d IDEBK
|d YDX
|d OPELS
|d EBLCP
|d UPM
|d OCLCF
|d OHS
|d OCLCO
|d D6H
|d GrThAP
|
| 019 |
|
|
|a 1007577005
|
| 020 |
|
|
|a 9780128124741
|q (electronic bk.)
|
| 020 |
|
|
|a 0128124741
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128124734
|
| 020 |
|
|
|a 0128124733
|
| 035 |
|
|
|a (OCoLC)1007290591
|z (OCoLC)1007577005
|
| 050 |
|
4 |
|a QP552.N39
|
| 072 |
|
7 |
|a NAT
|x 019000
|2 bisacsh
|
| 072 |
|
7 |
|a SCI
|x 070030
|2 bisacsh
|
| 082 |
0 |
4 |
|a 599.0188
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
4 |
|a The role of neuropeptides in addiction and disorders of excessive consumption /
|c edited by Todd E. Thiele.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c [2017].
|
| 264 |
|
4 |
|c Ã2017
|
| 300 |
|
|
|a 1 online resource :
|b illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v v. 136
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 505 |
0 |
|
|a ""Front Cover""; ""The Role of Neuropeptides in Addiction and Disorders of Excessive Consumption""; ""Copyright""; ""Contents""; ""Contributors""; ""Preface""; ""Chapter One: Neuropeptides and Addiction: An Introduction""; ""References""; ""Chapter Two: Corticotropin-Releasing Factor (CRF) and Addictive Behaviors""; ""1. Introduction""; ""2. CRF Stress Systems""; ""3. CRF, the HPA Axis, and Addiction""; ""4. Extrahypothalamic CRF Systems""; ""5. Role for CRF-CRF1 Systems in Animal Models of Addiction""; ""6. Central Extended Amygdala""; ""6.1. Cellular Mechanisms of CRF""
|
| 505 |
8 |
|
|a ""7. Ventral Tegmental Area""""8. Prefrontal Cortex""; ""9. Compulsive Eating""; ""10. Conclusion""; ""Acknowledgments""; ""References""; ""Chapter Three: Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction""; ""1. Introduction""; ""1.1. Stress, Addiction, and Kappa Opioid Receptors""; ""1.2. Modulation of Neurotransmitter Signaling by Kappa Opioid Receptors""; ""1.3. Kappa Opioid Receptors in the NAc""; ""1.4. Kappa Opioid Receptors in the VTA""; ""1.5. Measuring Dynorphin Levels""; ""1.6. Opponent Process Theory of Addiction""
|
| 505 |
8 |
|
|a ""1.7. Sex Differences in Kappa Opioid Receptor Function""""2. Ethanol and Kappa Opioid Receptors""; ""2.1. Kappa Opioid Receptors and Ethanol Consumption""; ""2.2. Kappa Opioid Receptors and Chronic Ethanol Exposure""; ""2.3. Ethanol Effects on the Dynorphin/Kappa Opioid Receptor System""; ""2.4. Ethanol, Kappa Opioid Receptors, and Dopamine""; ""3. Cocaine and Kappa Opioid Receptors""; ""3.1. Chronic Stress, Kappa Opioid Receptors, and Cocaine""; ""3.2. Timing of Kappa Opioid Receptor Activation, Dopamine Deficits, and Cocaine Effects""; ""3.3. Kappa Opioid Receptors and DATs""
|
| 505 |
8 |
|
|a ""3.4. Cocaine, Kappa Opioid Receptors, and DATs""""3.5. Reinstatement of Cocaine Self-Administration""; ""4. Obesity and Kappa Opioid Receptors""; ""4.1. The Dynorphin/Kappa Opioid Receptor System and Hereditary Obesity""; ""4.2. Dynorphin/Kappa Opioid Receptor System and Palatable Food Consumption""; ""4.3. Dynorphin/Kappa Opioid Receptor System and Food Deprivation""; ""5. Kappa Opioid Receptor-Based Therapeutics""; ""References""; ""Further Reading""; ""Chapter Four: The Role of the Ghrelin System in Drug Addiction""; ""1. Introduction""; ""2. Ghrelin and Alcohol""
|
| 505 |
8 |
|
|a ""2.1. Preclinical Evidence""""2.2. Clinical Evidence""; ""3. Ghrelin and Stimulants""; ""3.1. Preclinical Evidence""; ""3.2. Clinical Evidence""; ""4. Ghrelin and Tobacco/Nicotine""; ""4.1. Preclinical Evidence""; ""4.2. Clinical Evidence""; ""5. Ghrelin and Opioids""; ""5.1. Preclinical Evidence""; ""6. Ghrelin and Cannabis""; ""6.1. Preclinical Evidence""; ""6.2. Clinical Evidence""; ""7. Conclusions""; ""Acknowledgments and Disclosures""; ""References""; ""Chapter Five: The Role of the Melanocortin System in Drug and Alcohol Abuse""; ""1. Introduction""; ""2. Melanocortin Receptors""
|
| 650 |
|
0 |
|a Neuropeptides.
|
| 650 |
|
0 |
|a Compulsive behavior.
|
| 650 |
|
7 |
|a NATURE / Animals / Mammals.
|2 bisacsh
|
| 650 |
|
7 |
|a SCIENCE / Life Sciences / Zoology / Mammals.
|2 bisacsh
|
| 650 |
|
7 |
|a Compulsive behavior.
|2 fast
|0 (OCoLC)fst00871935
|
| 650 |
|
7 |
|a Neuropeptides.
|2 fast
|0 (OCoLC)fst01036450
|
| 650 |
|
2 |
|a Neuropeptides.
|
| 650 |
|
2 |
|a Compulsive Behavior.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Thiele, Todd E.
|q (Todd Eric),
|d 1967-.
|
| 776 |
0 |
8 |
|c Original
|z 9780128124734
|z 0128124733
|w (OCoLC)985078855
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 136.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/00747742/136
|z Full Text via HEAL-Link
|
